Sign in
CompletedNo phase

Family Navigation to Improve ADHD Treatment Adherence for Minority Children

Key facts

Who runs it
Children's Hospital Medical Center, Cincinnati
Where
Cincinnati, United StatesSee the site
Trial code
Status
Completed
People taking part
108 people enrolled
Started
14 May 2021
Ended
30 Jul 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • I2-ART
  • Usual care
Record updated
14 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Currently providing care for children with ADHD as psychologists, general pediatricians, or developmental pediatricians
  • > 18 years old
  • Any race/ethnicity
  • Having experience working as family navigator and/or community health worker
  • Latinx (Lx) or African American (AA)
  • > 18 years old
  • Phase 1a: current or former caregiver of a child with ADHD, with and without experience with ADHD treatment
  • Phases 1b and 2: current caregiver of a child (aged 7-11 years) with ADHD who is ADHD treatment-naïve at study enrollment
  • Lx or AA
  • > 18 years old

Who cannot take part

  • Unable to read/speak either English or Spanish
  • Family navigators
  • Unable to read/speak either English or Spanish
  • Caregivers
  • Unable to read/speak either English or Spanish

Other criteria

  • Clinicians

Where in United States

  • Cincinnati Children's Hospital Medical CenterCincinnati, United States

About the trial

What the trial wants to find out

ADHD is the most common pediatric neurodevelopmental disorder and is associated with significant long-term impairments. Current guidelines recommend stimulant medication and/or behavioral therapy as first-line treatments for ADHD. Despite evidence that consistent treatment is important for effectively managing ADHD symptoms, treatment adherence remains suboptimal and is especially problematic among minority children. Hypothesized reasons for racial/ethnic disparities in ADHD treatment include uncertainties about medication efficacy and side effects, distrust of the health care system, and decreased access to mental health services. This study aims to develop and test the I2-ART intervention to improve treatment adherence in minority (Latinx and African American) children with ADHD. The proposed study involves three ORBIT phases: During phase 1a, the investigators will conduct focus groups with key stakeholders (i.e., caregivers, clinicians, and family navigators, n=24) to identify and develop I2-ART's basic elements. Next, during phase 1b, the investigators will train four family navigators to implement I2-ART with caregivers of treatment-naïve children with ADHD (n=8-12) in order to determine feasibility and acceptability. In phase 2, the investigators will use phase 1b findings to modify I2-ART as needed, and then will evaluate the preliminary efficacy of the revised I2-ART (n=40), compared to the "usual care" control condition (n=20), on ADHD treatment adherence. The preliminary data collected during the proposed study will inform a subsequent R01 randomized controlled trial to examine I2-ART efficacy.

The 2 groups in the trial

  • I2-ART GroupExisting treatment, for comparison

    I2-ART intervention will be modeled based on the Parent Empowerment Program model. It will use methods of adult learning, direct instruction to share knowledge or techniques for practice, group support, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). I2-ART training includes 40 hours of didactic and interactive sessions (10 sessions of 4 hours each) covering the following areas: 1) conceptual framework, 2) listening, engagement, and boundary-setting skills; 3) ADHD psychoeducation (e.g., diagnosis, treatment, shared decision-making tools), and 4) service options. The caregivers in the I2-ART group will receive the intervention for 3 months. The I2-ART will be implemented by the family navigators and will include a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.

    Treatment: I2-ART

  • Control GroupPlacebo, for comparison

    The caregivers in the control group will receive "usual care."

    Treatment: Usual care

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Family Navigator Intervention to Improve ADHD- Related Treatment Adherence (I2-ART) for Minority Children
Record updated
14 August 2026